GlassScriptPrepare for your visit
Amanbir Sohal
Pulmonary Disease · Tomball, TX · NPI 1942640560
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$8,162.95
in general payments reported to CMS, 2019-2025 · $2,207 in 2025
The $2,207 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Who reported paying
General payments only, top 6 by amount.
- Intuitive Surgical, INC. $3,006.88
- Pulmonx Corporation $1,375.00
- Glaxosmithkline, LLC. $547.60
- Astrazeneca Pharmaceuticals LP $524.76
- Regeneron Healthcare Solutions, INC. $451.16
- Actelion Pharmaceuticals US, INC. $286.08
Drugs and devices associated with these payments
Da Vinci Surgical System Zephyr Endobronchial Valve Dupixent Pulmonx Chartis Tablet Console Chartis Catheter Zephyr Delivery Catheter Arikayce Inspire Trelegy Ellipta Uptravi Arexvy Opsumit
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Amanbir Sohal listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/703768/amanbir-sohal